Locally recurrent prostate cancer with RB1/TP53 alterations successfully treated by salvage focal brachytherapy: a case report.

Takahiro Komori, Takeo Kosaka, Tomoki Tanaka, Keitaro Watanabe, Yota Yasumizu, Shuji Mikami, Mototsugu Oya

Open access · greenAbstract readCase Reports

In one paragraph

Article in American journal of clinical and experimental urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.3field-weighted citation impact, top 36% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation.Genes & cancer · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Takahiro KomoriDepartment of Urology, Keio University School of Medicine Tokyo, Japan.

Takeo KosakaDepartment of Urology, Keio University School of Medicine Tokyo, Japan.

Tomoki TanakaDepartment of Radiology, Keio University School of Medicine Tokyo, Japan.

Keitaro WatanabeDepartment of Urology, Keio University School of Medicine Tokyo, Japan.

Yota YasumizuDepartment of Urology, Keio University School of Medicine Tokyo, Japan.

Shuji MikamiDepartment of Pathology, National Hospital Organization Saitama Hospital Tokyo, Japan.

Mototsugu OyaDepartment of Urology, Keio University School of Medicine Tokyo, Japan.

Keio University · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma transcriptional corepressor 1 (RB1) and tumor protein p53 (TP53) are well-known tumor suppressor genes; their alterations are associated with poor prognosis in human malignancies and quite rare in locally recurrent cases. The patient was a 58-year-old man who was diagnosed with cT1cN0M0 prostate cancer with Gleason score of 3+3=6 and underwent brachytherapy as the initial treatment. Local recurrence was detected in the left lobe of the prostate 154 months later and whole-exome sequencing that was performed at the request of the patient revealed RB1 loss-of-heterozygosity and TP53 p.I162Rfs*27 mutations. He underwent salvage focal brachytherapy with

Indexed as

prostate cancerRB1salvage focal brachytherapyTP53tumor suppressor gene

Identifiers

PMID37645609

PMCPMC10461036

OpenAlexW4386271292

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.